Skip to main content

Market Overview

Recap: 10x Genomics Q1 Earnings



Shares of 10x Genomics (NASDAQ:TXG) remained unaffected after the company reported Q1 results.

Quarterly Results

Earnings per share rose 186.96% over the past year to $0.66, which beat the estimate of $0.50.

Revenue of $231,200,000 higher by 34.42% from the same period last year, which missed the estimate of $232,000,000.


10x Genomics hasn't issued any earnings guidance for the time being.

10x Genomics hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: May 13, 2021

Time: 09:00 AM

ET Webcast URL:

Recent Stock Performance

Company's 52-week high was at $203.25

52-week low: $72.04

Price action over last quarter: down 7.08%

Company Overview

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others.


Related Articles (TXG)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at